Dexmedetomidine, midazolam; fentanyl
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intubated and Mechanically Ventilated Pediatric Subjects
Conditions
Intubated and Mechanically Ventilated Pediatric Subjects
Trial Timeline
Nov 1, 2008 → Apr 1, 2010
NCT ID
NCT00652028About Dexmedetomidine, midazolam; fentanyl
Dexmedetomidine, midazolam; fentanyl is a phase 2 stage product being developed by Pfizer for Intubated and Mechanically Ventilated Pediatric Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT00652028. Target conditions include Intubated and Mechanically Ventilated Pediatric Subjects.
What happened to similar drugs?
2 of 2 similar drugs in Intubated and Mechanically Ventilated Pediatric Subjects were approved
Approved (2) Terminated (0) Active (0)
✅Remimazolam Tosilate for Injection + Remimazolam Tosilate for InjectionJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00652028 | Phase 2 | Completed |
Competing Products
3 competing products in Intubated and Mechanically Ventilated Pediatric Subjects
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 39 |
| Dexmedetomidine HCL Injection + Midazolam Injection | Pfizer | Approved | 43 |
| Vadadustat 900mg + Vadadustat 1200mg + Placebo | Akebia Therapeutics | Phase 2/3 | 35 |